No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
APLMW Apollomics
- 0.011
- +0.001+10.00%
Close Jul 19 16:00 ET
0.011High0.009Low
0.011High0.009Low2.00KVolume0.009Open0.010Pre Close19.00Turnover0.00%Turnover Ratio--P/E (Static)0Shares0.01652wk High--P/B0Float Cap0.00952wk Low--Dividend TTM0Shs Float0.016Historical High--Div YieldTTM25.00%Amplitude0.009Historical Low0.009Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
News
Express News | Apollomics - Sanjeev Redkar Co-Founder & President, Peony Yu, Chief Medical Officer to Transition to Consulting Roles
Express News | Apollomics Inc - Expects Over 50% Reduction in Ongoing Expenses
Express News | Apollomics Inc - Capital to Fund Operations Into Q3 2025
Express News | Apollomics Inc - Expects Significant Reductions in Operating Expenses
Express News | Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Apollomics Announces Presentation at the 2024 BIO International Convention
FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug can
